Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 10/20 | 0.67 |
| ▸ | BLM | P54132 | 5/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | RECQL | P46063 | 3/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | APEX1 | P27695 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.67 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.67 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.67 |
| ▸ | DRD2 | P14416 | 1/20 | 0.67 |
| ▸ | DRD1 | P21728 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7152531 | 1.00 | ADRB2 (0.67) | ADRB2BLMTDP1MAPTRECQL | |
| SCHEMBL28290091 | 0.85 | BLM (0.67) | ADRB2BLMTDP1MAPTRECQL | |
| SCHEMBL15061878 | 0.84 | BLM (0.65) | ADRB2BLMTDP1MAPTRECQL | |
| SCHEMBL1311066 | 0.81 | ADRB2 (0.59) | ADRB2TDP1ADRB1NFKB1TSHR | |
| SCHEMBL6462710 | 0.81 | ADRB2 (0.59) | ADRB2TDP1ADRB1NFKB1TSHR | |
| SCHEMBL1311067 | 0.81 | ADRB2 (0.59) | ADRB2TDP1ADRB1NFKB1TSHR | |
| SCHEMBL14291852 | 0.81 | ADRB2 (0.62) | ADRB2TDP1ADRB1CYP3A4NFKB1 | |
| SCHEMBL19236388 | 0.81 | ADRB2 (0.62) | ADRB2TDP1ADRB1CYP3A4NFKB1 | |
| SCHEMBL14622394 | 0.81 | ADRB2 (0.54) | ADRB2TDP1ADRB1NFKB1TSHR | |
| L-Norepinephrine SCHEMBL3489077 | 0.80 | TDP1 (1.00) | ADRB2BLMTDP1MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107271665-B | Test strip for detecting salbutamol and application thereof | 北京望尔生物技术有限公司 | 2020-06-23 | — | — | CN | claimed |
| CN-107271665-B | Test strip for detecting salbutamol and application thereof | 北京望尔生物技术有限公司 | 2020-06-23 | — | — | CN | disclosed |
| EP-3201171-B1 | METHOD OF PREPARING INTERMEDIATE OF SALMETEROL | AMPHASTAR NANJING PHARMACEUTICALS INC (CN) | 2020-04-15 | — | — | EP | disclosed |
| CN-109694376-B | Beta-beta2Receptor agonist compounds and their use in the treatment of asthma | 黑龙江中医药大学 | 2019-12-27 | — | — | CN | disclosed |
| CN-109694376-A | Novel β2Receptor agonist compounds and its treatment asthma class disease purposes | 黑龙江中医药大学 | 2019-04-30 | — | — | CN | disclosed |
| WO-2017168431-A1 | PROCESS FOR THE PREPARATION OF SALMETEROL XINAFOATE | DAVULURI RAMAMOHAN RAO (IN) | 2017-10-05 | — | — | WO | disclosed |
| WO-2017168431-A1 | PROCESS FOR THE PREPARATION OF SALMETEROL XINAFOATE | DAVULURI RAMAMOHAN RAO (IN) | 2017-10-05 | — | — | WO | disclosed |
| US-9447067-B2 | Method of preparing intermediate of salmeterol | Amphastar Pahmaceuticals, Inc. (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447067-B2 | Method of preparing intermediate of salmeterol | Amphastar Pahmaceuticals, Inc. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160096816-A1 | METHOD OF PREPARING INTERMEDIATE OF SALMETEROL | AMPHASTAR NANJING PHARMACEUTICALS INC. (CN) | 2016-04-07 | — | — | US | disclosed |
| US-4654371-A | ANTI-OBESITY, HYPOGLYCEMIA AGENTS | BEECHAM GROUP P.L.C. (GB) | 1987-03-31 | — | — | US | disclosed |
| US-4478849-A | HYPERGLYCEMIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1984-10-23 | — | — | US | disclosed |
| US-4396627-A | HYPOGLYCEMIC AGENTS, TREATMENT OF OBECITY | BEECHAM GROUP LIMITED (GB) | 1983-08-02 | — | — | US | disclosed |
| EP-0006735-B1 | SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | BEECHAM GROUP PLC (GB) | 1983-06-15 | — | — | EP | disclosed |
| EP-0023385-B1 | ETHANAMINE DERIVATIVES, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1982-12-15 | — | — | EP | disclosed |
| EP-0021636-B1 | SECONDARY AMINES, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1982-12-01 | — | — | EP | disclosed |
| US-4338333-A | ANTIOBESITY, HYPOGLYCEMIC | BEECHAM GROUP LIMITED (GB) | 1982-07-06 | — | — | US | disclosed |
| EP-0023385-A1 | Ethanamine derivatives, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-02-04 | — | — | EP | disclosed |
| EP-0021636-A1 | Secondary amines, their preparation and use in pharmaceutical compositions | BEECHAM GROUP PLC (GB) | 1981-01-07 | — | — | EP | disclosed |
| EP-0006735-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096816-A1 | METHOD OF PREPARING INTERMEDIATE OF SALMETEROL | HSD3B1, HSD3B2, MSMO1 | ADRB2 51/4885BLM 579/4885TDP1 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.